摘要
目的研究免疫治疗药物治疗非小细胞肺癌的有效性和安全性。方法选取2018年9月-2021年9月在我院诊治的86例非小细胞肺癌患者为研究对象,采用随机数字表法分为对照组和观察组,各42例。对照组采用顺铂+多西他赛治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,比较两组临床疗效、血管内皮生长因子(VEGF)、血清肿瘤标志物水平、毒副反应发生率。结果观察组治疗总有效率为71.43%,高于对照组的57.14%(P<0.05);两组治疗后VEGF均低于治疗前,且观察组低于对照组(P<0.05);治疗后两组糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)均低于治疗前,且观察组低于对照组(P<0.05);观察组毒副反应发生率为52.83%,与对照组的50.00%比较,差异无统计学意义(P>0.05)。结论免疫治疗药物治疗非小细胞肺癌可提高治疗总有效率,降低血清肿瘤标志物水平,且不良反应少,具有重要的临床应用价值。
Objective To study the efficacy and safety of immunotherapy drugs in the treatment of non-small cell lung cancer.Methods A total of 86 patients with non-small cell lung cancer diagnosed and treated in our hospital from September 2018 to September 2021 were selected as study subjects.They were divided into control group and observation group according to random number table method,with 42 cases in each group.The control group was treated with cisplatin+docetaxel,and the observation group was treated with carrelizumab on the basis of the control group.The clinical efficacy,vascular endothelial growth factor(VEGF),serum tumor marker levels,and incidence of toxic and side effects were compared between the two groups.Results The total effective rate of the observation group was 71.42%,which was higher than 57.14%of the control group(P<0.05).VEGF in the two groups after treatment was lower than before treatment,and the observation group was lower than the control group(P<0.05).After treatment,carbohydrate antigen 125(CAl25),carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)in the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05).The incidence of side effects in the observation group was 52.83%,compared with 50.00%in the control group,and the difference was not statistically significant(P>0.05).Conclusion Immunotherapy drugs for non-small cell lung cancer can improve the total effective rate of treatment,reduce the level of serum tumor markers,and have fewer adverse reactions,which has important clinical application value.
作者
侯晓杰
HOU Xiao-jie(School of Basic Medicine,Qingdao University,Qingdao 266071,Shaanxi,China;Hyperbaric Oxygen Department of Linyi Central Hospital,Linyi 276400,Shandong,China)
出处
《医学信息》
2022年第18期118-120,共3页
Journal of Medical Information
作者简介
侯晓杰(1984.2-),女,山东寿光人,本科,主治医师,主要从事肿瘤药理学研究。
